logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain

< Back

Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain

Drugs

Anaesthetics, Pain Relief and ITU

March 2019


Tanezumab is in clinical development for the treatment of moderate to severe chronic pain associated with osteoarthritis and chronic low back pain. Pain is an unpleasant sensory experience associated with damage to body tissues due to an injury, physical pressure, or inflammation of some part of the body. Chronic pain is persistent or recurrent and lasts for longer than 12 weeks. Moderate pain interferes significantly with daily living activities, and severe pain is disabling and causes an inability to perform daily living activities. Effective long-term treatment options for managing moderate to severe chronic pain are limited. Currently available pain medicines like opioids and analgesics may increase the risks of addiction, gastrointestinal, cardiovascular and renal problems.
Tanezumab is a type of monoclonal antibody, which works by selectively targeting, binding to and inhibiting nerve growth factor (NGF). NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. By inhibiting NGF, tanezumab may help to keep pain signals produced by muscles, skin and organs from reaching the spinal cord and brain. Tanezumab has a novel mechanism that acts in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs, and may offer an alternative treatment option for managing chronic pain.

Innovation Observatory Voice 16

Is tanezumab available in the uk

Donald maccaskill - Posted ago

    Hello Donald. Thank you for your comment. This drug is currently still in development and not yet released in the UK. If you have any further questions please email us on info@io.nihr.ac.uk

    Abby Scott - Posted ago

Why do the major newspapers post articles that state how beneficial tanezumab is for neuropathic pain when it is unavailable on the NHS. It gives false hope to sufferers. Is it available privately?
Regards Rod

Rod Horne - Posted ago

    Hello Rod

    I’m afraid once our reports are submitted to NICE for further assessment we don’t track their licencing or availability. I can only recommend you reach out to your doctor for further information on Tanexumab. If you have any further queries please email info@io.nihr.ac.uk

    Abby Scott - Posted ago

Following 2 unsuccessful lower back ops o cannot take anti-inflammatory meds after AKI causing total kidney collapse during 2nd op.
I know have debilitating chronic pain can you advise when Tanezumab may be available in UK?

Marilyn Koops - Posted ago

    Hello Marilyn

    I’m afraid once our reports are submitted to NICE for further assessment we don’t track their licencing or availability. I can only recommend you reach out to your doctor for further information. If you have any further queries please email info@io.nihr.ac.uk

    Abby Scott - Posted ago

Is tanezumab available for treatment of chronic back pain which is affecting my mobility especially in the morning.

Joyce Boyer - Posted ago

    Hello Joyce

    I’m afraid I don’t have any further information regarding the availability of Tanezumab. I can only recommend you reach out to your doctor for further information. If you have any further queries please email info@io.nihr.ac.uk

    Abby Scott - Posted ago

Is there any scheduled date as to when this may become available in the UK?

Paul Bradney - Posted ago

    Hello Paul

    I’m afraid once our reports are submitted to NICE for further assessment we don’t track their licencing. I can only recommend you reach out to your doctor for further information. If you have any further queries please email info@io.nihr.ac.uk

    Abby Scott - Posted ago

Hi is Tanezumab available yet in Scotland 19/10/2020

Joseph Doyle - Posted ago

    Hello Joseph

    I’m afraid once our reports are submitted to NICE for further assessment we don’t track their licencing. I can only recommend you reach out to your doctor for further information. If you have any further queries please email info@io.nihr.ac.uk

    Abby Scott - Posted ago

When is this available in the UK please.

Karen Bainbridge - Posted ago

    Hello Karen

    I’m afraid once our reports are submitted to NICE for further assessment we don’t track their licencing. I can only recommend you reach out to your doctor for further information. If you have any further queries please email info@io.nihr.ac.uk

    Abby Scott - Posted ago

I have been in chronic pain for 11 years after an operation for a slipped disc. It has left me with chronic pain in my foot. I take Pregablin at present but it doesn’t take away the pain. How can I find out if this drug would be effective for my condition and when it’s been approved.

Carol Hale - Posted ago

    Hello Carol

    I’m afraid once our reports are submitted to NICE for further assessment we don’t track their licencing. I can only recommend you reach out to your doctor for further information. If you have any further queries please email info@io.nihr.ac.uk

    Abby Scott - Posted ago

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts